In addition, interleukin‐11 (IL‐11), interleukin‐16 (IL‐16), CCL22, and MIP‐3β which have been previously associated with cardiac fibrosis, (Schafer et al., 2017; Tamaki et al., 2013) or cardiovascular disease (Kimura et al., 2018; Safa et al., 2016), and fractalkine (CX3CL1), a chemokine associated with poorer cardiac functional outcome and increased mortality in MI patients (Boag et al., 2015), showed a similar trend of reduction following navitoclax treatment. Here, IL11 is linked to cardiovascular disorder.